Cipla therapeutics and siga technologies announce strategic partnership to support innovation and provide access to novel antibacterial drugs against biothreats

Mumbai, india, march 23, 2021 /prnewswire/ -- cipla therapeutics, an affiliate of cipla limited (bse: 500087) (nse: cipla eq) (herein referred to as "cipla") and siga technologies, inc. (siga) (nasdaq: siga), a commercial-stage pharmaceutical company focused on the health security market announced entering into a strategic partnership to deliver sustained innovation and access to novel antibacterial drugs, particularly against biothreats. the world health organization has declared that anti-microbial resistance (amr) is one of the top 10 global public health threats facing humanity2 which puts at risk the effective prevention and treatment of a wide range of infections.
SIGA Ratings Summary
SIGA Quant Ranking